Sirnaomics Ltd. reported that a poster with positive clinical data of STP705 for focal fat reduction (FFR) was presented at the 2023 Fall Clinical Dermatology Conference, which took place October 22-25 in Las Vegas. The safety and efficacy results of this Phase I study support further investigation of STP705 as a potential alternative to other injectables for FFR. The poster, titled "Phase I Study to Evaluate the Safety and Tolerability of Subcutaneous Injection of STP705 in Adult Subjects Undergoing Abdominoplasty," was presented by Dr. Mark S. Nestor's team from Center for Clinical and Cosmetic Research, Aventura Florida.

The presentation provided a summary of the Phase I study, which aimed to explore the safety and tolerability of STP705 in patients undergoing abdominoplasty, while making initial observations on the efficacy of STP705 to induce adipocyte apoptosis for fat reduction. Results include: STP705 was well-tolerated at all doses, concentrations, and volumes. STP705 demonstrated an excellent safety with very few local skin reactions (LSRs).

There were very few observed treatment-associated adverse reactions and these resolved without intervention. STP705 may have a favorable safety profile when administered locally for the purpose of fat reduction. Histologic analysis performed on excised tissue samples provided further evidence of STP705's activity in adipocyte destruction, which occurred in a suggested dose-response manner; this will guide future clinical dosing parameters for optimal efficacy and safety.

The study protocol consisted of 3 treatment cycles administered 28 days apart. Each treatment cycle calls for 7 subcutaneous injections consisting of either 120 g, 240 g, or 360 g of STP705 in 0.5 and 1.0 ml doses (per injection) and 1.0 ml of placebo. Patients were randomized in a double-blind manner and injected in seven 1 cm2 areas across the lower abdomen.

Eight subjects aged 18-65 received injections with follow-ups occurring at 2 and 7 days post procedure. Tissue samples from each of the 7 injection sites were harvested from the total abdominoplasty excisional specimens obtained 28 days after the final round of injections. Safety assessments were conducted throughout the study, including evaluation of LSRs, and collection of any adverse events.

Lipolytic and inflammatory effects of STP705 were assessed by blinded histologic analysis of harvested tissue samples, and each of the samples was given a histology score corresponding to the degree of the observed inflammatory response.